We are thrilled to announce multi-target research collaborations with Eli Lilly and Company and Novartis – Isomorphic Labs
Sergei Yakneen, Chief Technology Officer at Isomorphic Labs, shared a post by Isomorphic Labs on LinkedIn:
“Newsflash! We are now partnered with Eli Lilly and Company and Novartis in deals worth up to nearly $3 billion, using our platform to develop new medicines against several challenging targets. This is showtime for our team and the AI tech we’ve been building for the last two years. Lilly and Novartis are two of the most sophisticated and forward-thinking pharma companies out there and are a pleasure to work with. Let’s go!”
Quoting Isomorphic Labs’s post:
“We are thrilled to announce multi-target research collaborations with Eli Lilly and Company and Novartis. These two partnerships have the potential to be worth nearly $3 billion to Isomorphic Labs, excluding any royalties that may result from future drug sales. Read more here.”
Source: Sergei Yakneen/LinkedIn and Isomorphic Labs/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023